BridgeBio Reports Strong Attruby Sales, Positive Phase 3 Data for BBP-418 & Encaleret, and Robust Pipeline Progress

summarizeResumen

This 8-K details a highly positive business update from BridgeBio Pharma, presented at the J.P. Morgan Healthcare Conference. The company demonstrated strong commercial momentum for its approved drug Attruby, with substantial Q4 revenue and market penetration. Critically, BridgeBio announced significant de-risking events for two late-stage pipeline assets: BBP-418, which received a positive FDA recommendation for traditional approval following strong Phase 3 interim data, and encaleret, which showed compelling Phase 3 results and is on track for an NDA submission. Additionally, the completion of Last Participant Last Visit (LPLV) for the infigratinib Phase 3 trial sets up a key near-term data readout. The announcement of a new ATTR-CM depleter program and positive Phase 2a data for PORT-77 further strengthens the long-term pipeline. With a robust cash position, BridgeBio appears well-funded to advance its diverse portfolio and execute on multiple potential product launches, justifying the stock's position near its 52-week high.

check_boxEventos clave

• Strong Attruby Commercial Performance

  BridgeBio reported preliminary Q4 2025 net product revenue of $146.0 million for Attruby, with 6,629 unique patient prescriptions and over 25% estimated new-to-brand share, indicating robust market uptake.

• BBP-418 Phase 3 Success & Regulatory Path

  Positive interim Phase 3 results for BBP-418 in LGMD2I/R9 demonstrated significant clinical benefit, leading the FDA to recommend a traditional full approval NDA submission in the first half of 2026.

• Encaleret Phase 3 Success & Regulatory Path

  The CALIBRATE Phase 3 trial for encaleret in ADH1 showed a compelling 76% responder rate, with an NDA submission planned for the first half of 2026. A Phase 3 trial for chronic hypoparathyroidism is also set to initiate in Summer 2026.

• Infigratinib Near-Term Catalyst

  The Last Participant Last Visit (LPLV) has been completed for the Phase 3 achondroplasia trial of infigratinib, with topline results anticipated by the end of Q1 2026.

auto_awesomeAnalisis

This 8-K details a highly positive business update from BridgeBio Pharma, presented at the J.P. Morgan Healthcare Conference. The company demonstrated strong commercial momentum for its approved drug Attruby, with substantial Q4 revenue and market penetration. Critically, BridgeBio announced significant de-risking events for two late-stage pipeline assets: BBP-418, which received a positive FDA recommendation for traditional approval following strong Phase 3 interim data, and encaleret, which showed compelling Phase 3 results and is on track for an NDA submission. Additionally, the completion of Last Participant Last Visit (LPLV) for the infigratinib Phase 3 trial sets up a key near-term data readout. The announcement of a new ATTR-CM depleter program and positive Phase 2a data for PORT-77 further strengthens the long-term pipeline. With a robust cash position, BridgeBio appears well-funded to advance its diverse portfolio and execute on multiple potential product launches, justifying the stock's position near its 52-week high.